Type 1 dendritic cells have been of interest in the last decade due to their specialized ability to directly activate CD8+ T cells [51]; numerous therapeutic strategies have targeted these immune cells in the treatment of melanoma [52]. This evidence concerns the gene CD8A and melanoma.